Insulet Corporation $PODD Holdings Cut by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. lessened its stake in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 77.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,600 shares of the medical instruments supplier’s stock after selling 26,404 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Insulet were worth $993,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PODD. Fifth Third Bancorp raised its holdings in shares of Insulet by 21.3% during the third quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier’s stock valued at $8,421,000 after purchasing an additional 11,334 shares during the last quarter. Maryland State Retirement & Pension System lifted its position in Insulet by 22.5% during the third quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier’s stock valued at $545,000 after purchasing an additional 768 shares during the period. Ritholtz Wealth Management bought a new position in Insulet during the third quarter valued at approximately $276,000. Jacobi Capital Management LLC bought a new position in Insulet during the third quarter valued at approximately $40,000. Finally, New York Life Investment Management LLC lifted its position in Insulet by 91.5% during the third quarter. New York Life Investment Management LLC now owns 21,015 shares of the medical instruments supplier’s stock valued at $2,742,000 after purchasing an additional 10,042 shares during the period.

Insulet Trading Up 0.0%

Shares of NASDAQ:PODD opened at $145.34 on Wednesday. The stock’s 50-day simple moving average is $142.16 and its two-hundred day simple moving average is $172.43. The stock has a market capitalization of $10.08 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 1.11 and a beta of 1.06. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the prior year, the firm earned $1.24 EPS. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. Analysts expect that Insulet Corporation will post 6.76 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Stifel Nicolaus decreased their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Leerink Partners boosted their target price on shares of Insulet from $143.00 to $167.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, TD Cowen restated a “hold” rating on shares of Insulet in a research note on Wednesday, November 4th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $185.67.

Get Our Latest Report on Insulet

About Insulet

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

See Also

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.